CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 61 enrolled
Drug / intervention
MRG003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04868344
NCT04868344Phase 1Completed
CompareCT.gov

An Open-Label, Dose-Finding, Phase I Study in Solid Tumors.

Shanghai Miracogen Inc.·interventional·Posted Apr 30, 2021·Updated Apr 30, 2021

In Brief

A Phase 1 clinical trial evaluating MRG003 for Advanced Solid Tumors. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG003, as well as immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG003 in patients with advanced solid tumors, including colorectal cancer, squamous cell carcinoma of head and neck, and nasopharyngeal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 30, 2021
Enrollment StartMay 9, 2018
Primary CompletionMar 29, 2021
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 5.2 years ago

Interventions

MRG003drug

Administered intravenously